<DOC>
	<DOCNO>NCT02828410</DOCNO>
	<brief_summary>This open label trail test hypothesize serum bovine immunoglobulin protein isolate ( SBI ) improve nutritional status quality life ( QOL ) patient ileal pouch anal anastomosis ( IPAA ) symptoms pouchitis . Subjects symptomatic IPAA receive two packet EnteraGam twice daily ( total daily dose 20 g SBI ) 24 week . The primary objective study determine whether SBI therapy lead improved nutritional status QOL . A secondary objective evaluate SBI management disease , include impact clinical symptom .</brief_summary>
	<brief_title>Nutritional Impact Serum-Derived Bovine Immunoglobulin Protein Isolate Subjects With IPAA</brief_title>
	<detailed_description />
	<mesh_term>Pouchitis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patient male female age 1875 year , inclusive . Patient history UC Crohn 's disease ( CD ) diagnose standard clinical , radiographic , endoscopic , histopathological criterion . Patient undergone total proctocolectomy IPAA surgery minimum 6 month prior screen . Patient symptom suggestive pouchitis include frequent bowel movement great equal seven per day ( â‰¥7 per day ) , one following : daily rectal bleeding , fecal urgency , abdominal cramp , fever &gt; 37.8oC ) . Patient capable understanding requirement study sign / date IRB approve informed consent form . Patient provide write informed consent . Patient know allergy hypersensitivity beef , beef product , ingredient use EnteraGam . Patient clinical sign symptom active infection . Patient antibiotic therapy ( pouchitis treatment ) time 30 day prior screen . Patient active alcohol drug abuse psychiatric disorder felt preclude / ability complete study . Patient , opinion investigator , poorly control / uncontrolled significant medical condition would interfere study . Positive stool test ( PCR ) C. difficile . Use antidiarrheal medication ( ADM ) . Exception : patient , opinion Investigator , stable treatment ADMs may enrol provided administration schedule intend maintain decrease study subject stable treatment ADMs least 30 day prior screen ; otherwise , agent prohibit study . Use investigational product participation clinical trial within past three month . Use biologic ( e.g. , infliximab , adalimumab ) within last 3 month . Patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>